# A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

> **NCT01219543** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 47 (actual)

## Conditions studied

- Solid Tumour
- Advanced Solid Malignancies
- Child-Pugh A to B7 Advanced Hepatocellular Carcinoma
- EGFR and/or ROS Mutant NSCLC
- Lung Metastasis Carcinoma
- Gastric Cancer

## Interventions

- **DRUG:** AZD1480 Daily
- **DRUG:** AZD1480 BID

## Key facts

- **NCT ID:** NCT01219543
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Compound development discontinued
- **Last updated:** 2013-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01219543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01219543, "A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01219543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*